Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole Inhalation Powder in Healthy Adult Subjects
NCT04872231Phase 1Completed
- Sponsor
- TFF Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of voriconazole in Invasive Pulmonary Aspergillosis (IPA) (10 arms), sponsored by TFF Pharmaceuticals. Primary endpoints: Number of participants who experience Adverse Events (AEs), Serious Adverse Events (SAEs) and withdrawals due to AEs, Number of participants who experience vital sign abnormalities and 8 more. Started Nov 2019; status: completed.
02
Drugs
voriconazole
03
Conditions
Invasive Pulmonary Aspergillosis (IPA)
Beyond the preview
Go deeper on NCT04872231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872231.